Medicare Enrolled
Dr. Khalid Mahmood, MD
Hematology & Oncology · Webster, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mahmood from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mahmood?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mahmood
Dr. Khalid Mahmood is a hematology & oncology specialist in Webster, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mahmood performed 37,651 Medicare services across 1,662 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mahmood received a total of $2,973 from 49 pharmaceutical and/or device companies across 123 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mahmood is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 25% volume in TX
$2,973 industry payments
Medicare Practice Summary
Medicare Utilization ↗37,651
Medicare services
Top 25% in TX for hematology & oncology
1,662
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,982 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
26,010 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
3,690 | $2 | $20 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
3,262 | $0 | $3 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
893 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
855 | $8 | $36 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
613 | $10 | $64 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
447 | $95 | $357 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
380 | $96 | $368 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
336 | $66 | $250 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
270 | $0 | $1 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
91 | $34 | $143 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
89 | $50 | $313 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
74 | $11 | $96 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
68 | $23 | $157 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
63 | $6 | $31 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
59 | $106 | $707 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
58 | $6 | $431 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
56 | $59 | $211 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
55 | $64 | $247 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
49 | $103 | $470 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
31 | $186 | $1,067 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
29 | $53 | $821 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
28 | $135 | $694 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
27 | $122 | $565 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
24 | $138 | $496 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
22 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
22 | $6 | $34 |
| Basic metabolic blood panel A blood test that measures a group of basic chemicals, including total calcium levels. |
19 | $8 | $49 |
| Automated red blood cell count An automated laboratory test that measures the number of red blood cells in a blood sample. |
18 | $4 | $23 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 13 | $90 | $657 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
69.7% high complexity
19.8% medium
10.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,973
Total received (2018-2024)
Avg $425/year across 7 years
Bottom 49% in TX for hematology & oncology
49
Companies
123
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,950 (99.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$23 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$770
2023
$909
2022
$968
2021
$12
2020
$80
2019
$134
2018
$100
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$293
Merck Sharp & Dohme LLC
$208
GlaxoSmithKline, LLC.
$153
GENZYME CORPORATION
$144
Eisai Inc.
$123
Janssen Biotech, Inc.
$115
Gilead Sciences, Inc.
$108
AstraZeneca Pharmaceuticals LP
$100
Astellas Pharma US Inc
$100
Celgene Corporation
$100
PFIZER INC.
$97
Mirati Therapeutics, Inc.
$92
SOBI, INC
$86
Sobi, Inc
$76
Lilly USA, LLC
$73
Tempus AI, Inc
$67
Rigel Pharmaceuticals, Inc.
$64
E.R. Squibb & Sons, L.L.C.
$63
JAZZ PHARMACEUTICALS INC.
$62
PharmaEssentia USA Corporation
$61
Takeda Pharmaceuticals U.S.A., Inc.
$54
Pharmacosmos Therapeutics Inc.
$51
ARRAY BIOPHARMA INC
$48
Seagen Inc.
$42
ABBVIE INC.
$39
Stemline Therapeutics Inc.
$39
Exelixis Inc.
$39
Genentech USA, Inc.
$34
CTI BioPharma Corp.
$33
Regeneron Healthcare Solutions, Inc.
$31
Adaptive Biotechnologies Corporation
$31
Pharmacyclics LLC, an AbbVie Company
$27
TerSera Therapeutics LLC
$27
Karyopharm Therapeutics Inc.
$23
Aveo Pharmaceuticals, Inc.
$22
Apellis Pharmaceuticals, Inc.
$22
Bayer HealthCare Pharmaceuticals Inc.
$21
EMD Serono, Inc.
$20
Mylan Institutional Inc.
$19
Blueprint Medicines Corporation
$19
Incyte Corporation
$19
Tactile Systems Technology Inc
$19
Sumitomo Pharma America, Inc.
$19
EISAI INC.
$17
Amgen Inc.
$16
Biogen, Inc.
$16
Sun Pharmaceutical Industries Inc.
$14
MorphoSys, US Inc.
$14
Fortovia Therapeutics, Inc.
$12
Top 3 companies account for 22.0% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALUNBRIG · AYVAKIT · Alecensa · BAVENCIO · BESPONSA · BESREMI · BLENREP · BOSULIF · CABLIVI · CABOMETYX · Cabometyx · DOPTELET · Doptelet · ELAHERE · ENHERTU · ENJAYMO · ERLEADA · FOTIVDA · Fabhalta · Flexitouch Plus · IBRANCE · IMBRUVICA · IMFINZI · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LORBRENA · LUMAKRAS · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NINLARO · Nubeqa · OGIVRI · OJJAARA · OPDIVO · ORGOVYX · Orserdu · PADCEV · PIQRAY · PROMACTA · REBLOZYL · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · TABRECTA · TECFIDERA · Tavalisse · Trodelvy · VENCLEXTA · VERZENIO · VONJO · Vonjo · XALKORI · XPOVIO · XTANDI · YONSA · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $8 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
180
Per 100K population
3.8
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE CLEAR LAKE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Mahmood is a mixed practice specialist, with above-average Medicare volume (top 25% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Mahmood experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Mahmood performed 26,010 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mahmood receive payments from pharmaceutical companies?
Yes. Dr. Mahmood received a total of $2,973 from 49 companies across 123 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mahmood's costs compare to other hematology & oncology specialists in Webster?
Dr. Mahmood's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mahmood) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Webster
Browse hematology & oncology specialists in Webster ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology